Table 1.
List of clinical trials with LSD1 inhibitors in human blood and bone marrow malignancies [127,128,129].
| Code | Title | Status | Conditions | Interventions |
|---|---|---|---|---|
| DRKS00006055 | Phase I/II study of sensitization of non-M3 acute myeloid leukemia (AML) blasts to all-trans retinoic acid (ATRA) by epigenetic treatment with tranylcypromine (TCP), an inhibitor of the histone lysine demethylase 1 (LSD1) | Recruiting | AML and Myelodysplastic syndrome | TCP| ATRA| AraC |
| EUCTR2013-002447-29 | A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL) | Not Recruiting | Refractory or Relapsed acute leukaemia | ORY-1001 |
| EUCTR2018-000482-36 | A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy | Ongoing | AML | ORY-1001|Etoposide| Carboplatin| Cisplatin |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) | Recruiting | AML and Myelodysplastic Syndrome | TCP| ATRA| cytarabine |
| NCT02842827 | IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies | Completed | AML and Myelodysplastic Syndrome | IMG-7289| ATRA |
| NCT03136185 | IMG-7289 in Patients With Myelofibrosis | Recruiting | Myelofibrosis| PPV-MF| PET-MF| PMF | IMG-7289 |